Visiogen, Inc. Receives FDA Approval to Expand its U.S. Clinical Trial.Expansion of Trial Will Allow Researchers to Further Validate Safety and Effectiveness of the Investigational Synchrony synchrony /syn·chro·ny/ (-krah-ne) the occurrence of two events simultaneously or with a fixed time interval between them. atrioventricular (AV) synchrony [R] Dual Optic Accommodating IntraocularLens IRVINE, Calif. -- Visiogen, Inc. of Irvine, California Irvine is an incorporated city in Orange County, California, United States. It is a planned city, mainly developed by the Irvine Company since the 1960s. Formally incorporated on December 28 1971, the 69.7 square mile (180.5 km²) city has a population of 202,079 (as of 2007). , announced it has received approval from the U.S. Food & Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for full expansion of its Phase III U.S. clinical trial for its Synchrony[R] dual optic accommodating intraocular lens Intraocular lens Lens made of silicone or plastic placed within the eye; can be corrective. Mentioned in: Cataract Surgery . Already approved for use throughout the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community , the Synchrony system is being studied in a multi-center trial in the U.S. to evaluate safety and effectiveness and the potential for near and intermediate vision without the use of spectacles in patients post cataract surgery Cataract Surgery Definition Cataract surgery is a procedure performed to remove a cloudy lens from the eye; usually an intraocular lens is implanted at the same time. Purpose The purpose of cataract surgery is to restore clear vision. . "Full expansion of the clinical trial for Synchrony is another significant step toward our ultimate goal of approval for use within the United States," according to Barbara Niksch, Vice President of Regulatory, Quality & Clinical Affairs at Visiogen. The proprietary Synchrony system, intended for use in cataract and refractive refractive capacity to refract light. refractive error a difference between the focal length of the cornea and lens, and the length of the eye, resulting in myopia or hyperopia. patients, incorporates a dual optic lens with an easy-to-use pre-loaded injector. The entire system is self-contained and ready for use without the need for lens handling. The dual optic lens can be inserted through a 3.6 - 3.8 mm clear-corneal incision. The single-piece silicone lens unfolds in the eye upon insertion and features two optics connected by a spring system. The springs connect a 5.5-mm high power anterior optic and a 6-mm negative power posterior optic; the spring action moves the front optic and changes the eye's focus from near to far. This unique combination of positive- and negative-powered optics is customized for each patient. To date, the Synchrony lens has been implanted in over 400 patients worldwide. The company announced that it had received the European CE Mark for the Synchrony[R] Dual Optic Accommodating IOL in June of 2006, which allows them to expand into post-marketing research studies within Europe to further build the scientific foundation for Synchrony. About Visiogen Visiogen, Inc. is focused on developing innovative products for cataract and refractive patients. Founded in Irvine, California, in 2001, Visiogen's first commercial application, Synchrony[R], a dual optic accommodating intraocular lens and pre-loaded injector, is currently in clinical studies in the U.S. and recently received the CE Mark in Europe. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion